Bayesian Capital Management’s AbCellera Biologics ABCL Stock Holding History

Bayesian Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36,090	Closed	-$233K	–	664
2023 Q2	$233K	Buy	36,090 +17,200	+91%	+$117K	0.03%	601
2023 Q1	$142K	Sell	18,890 -16,500	-47%	-$150K	0.02%	648
2022 Q4	$359K	Buy	35,390 +500	+1%	+$5.78K	0.05%	438
2022 Q3	$345K	Buy	34,890 +8,100	+30%	+$88.9K	0.07%	371
2022 Q2	$285K	Sell	26,790 -910	-3%	-$7.71K	0.05%	499
2022 Q1	$270K	Buy	+27,700	New	+$262K	0.04%	553
2021 Q3	–	Sell	-22,900	Closed	-$504K	–	364
2021 Q2	$504K	Buy	+22,900	New	+$631K	0.13%	189

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Bayesian Capital Management's ABCL Position: Q3 2023 in Review

Bayesian Capital Management sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 36,090 shares — an estimated $233K sold.

Bayesian Capital Management first reported a position in ABCL in Q2 2021 and held it in 7 quarters. The position peaked at $504K in Q2 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

Bayesian Capital Management reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
Bayesian Capital Management sold 36,090 AbCellera Biologics shares in Q3 2023, an estimated $233K.
Bayesian Capital Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 7 quarters.
Bayesian Capital Management's AbCellera Biologics position peaked at $504K in Q2 2021.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.